DUBLIN–(BUSINESS WIRE)–The “Presbyopia – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.
This “Presbyopia – Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Presbyopia pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The assessment part of the report embraces, in depth Presbyopia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Presbyopia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Presbyopia.
- In the coming years, the Presbyopia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics that are working to assess challenges and seek opportunities that could influence Presbyopia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A detailed portfolio of major pharma players who are involved in fueling the Presbyopia treatment market. Several potential therapies for Presbyopia are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Presbyopia market size in the coming years.
- Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Presbyopia) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Presbyopia Emerging Drugs Chapters
This segment of the Presbyopia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Presbyopia Emerging Drugs
CSF-1: Orasis Pharmaceuticals
CSF-1 is a novel presbyopia corrective eye drop being developed to improve the quality of life for people with presbyopia. CSF-1 is a preservative-free solution that contains a proprietary combination of low-dose pilocarpine and multi-faceted vehicle. Clinical trial results to date have demonstrated significant improvements in near vision and an excellent safety profile in people with presbyopia. In the Phase 3 studies, CSF-1 achieved statistically significant distance-corrected near visual acuity (DCNVA) and no loss of 1-line or more in distance or night vision.
UNR844-Cl: Novartis
UNR844-Cl is an ester of naturally occurring R-lipoic acid and choline. Previously called EV06 ophthalmic solution, UNR844 targets directly the flexibility and accommodative ability of the crystalline lens. It breaks disulfide bonds, which are thought to harden the lens over time. By disrupting these bonds, the lens becomes more elastic and regains some functionality.
Presbyopia: Therapeutic Assessment
This segment of the report provides insights about the different Presbyopia drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Presbyopia
There are approx. 12+ key companies which are developing the therapies for Presbyopia. The companies which have their Presbyopia drug candidates in the most advanced stage, i.e. phase III include, Orasis Pharmaceuticals.
Phases
The report covers around 12+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Presbyopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Products have been categorized under various ROAs such as
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
- Molecule Type
Products have been categorized under various Molecule types such as
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Presbyopia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Presbyopia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Presbyopia drugs.
Presbyopia Report Insights
- Presbyopia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Presbyopia Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Players
- Orasis Pharmaceuticals
- Novartis
- Cellix Bio
- Visus Therapeutics
- AbbVie
- Vyluma
- Lenz Therapeutics
- Ocuphire Pharma
- JIXING Pharmaceuticals
- Eyenovia
Key Products
- CSF-1
- UNR844-Cl
- CLX-OPH-561
- VTI-001
- AGN-190584
- NVK029
- ACECLIDINE
- Nyxol
- MicroLine
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/rknub0
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900